Share this article:
Infecting Mosquitoes with Bacteria So They Can’t Infect Us with Viruses Like Zika and Dengue
Mosquitoes and their itchy bites are more than just an annoyance. They transmit dangerous viruses with deadly consequences – making them the most lethal animal on Earth. It’s the Aedes aegypti and Aedes albopictus mosquito species that are behind outbreaks of dengue virus, Zika virus, yellow fever virus and Chikungunya virus, responsible for over 100 million human cases around the world annually. And they’re expanding their habitat around the world as the global climate warms, bringing them into contact with more potential victims who have less immunity and increased susceptibility to these mosquito-transmitted viruses.
A vaccine can provide the recipient with immunity to one or two of these viruses at a time. But there’s another way to tackle these diseases: by going after the insects. Targeting the mosquito population as a whole or their ability to transmit disease takes aim at all these viruses at the same time.
As the U.S. enters another mosquito season, mosquito control districts in Florida and California are preparing new strategies to combat mosquitoes and the viruses they transmit. They’re trying out one of two new mosquito management methods made possible by a bacterium called Wolbachia pipientis.
A bacterium that’s our enemy’s enemy
Wolbachia are bacteria naturally found in insects throughout the world. They live inside a host organism’s cells. From there, Wolbachia are able to manipulate their host in many ways – things like increasing the number of eggs a host lays or even changing the host’s sex from male to female by manipulating its hormones.
Researchers discovered in 2008 that Wolbachia in fruit flies protect their hosts from fruit fly viruses. That realization got them wondering: Could Wolbachia also protect Aedes aegyptimosquitoes from viruses that cause human diseases?
Aedes aegypti mosquitoes don’t naturally carry Wolbachia. But consistent with the fruit fly studies, when researchers infected Aedes aegypti in the lab, the viruses they carry replicated less. Fewer of the infectious bits of the disease-carrying virus inside the mosquito meant disease transmission was limited – they were less likely to be passed on when mosquitoes fed on their prey.
Researchers in Australia, the United States and elsewhere are currently investigating the reasons why Wolbachia limit viruses. Some hypothesize Wolbachia improves the mosquitoes’ immunity to the virus, while other research, including my own, suggests Wolbachia steals key nutrients the virus needs. Both may be true.
The real need to employ this strategy now is motivating field trials to release Wolbachia-infected mosquitoes in several regions of the world.
Vector competency: The female approach
Only female mosquitoes bite and transmit viruses. Thus, the most powerful approach to reducing virus spread is limiting viruses in the female mosquito.
Wolbachia bacteria are transmitted from mother to offspring. If you introduce Wolbachia-infected female mosquitoes to a population, all offspring will have Wolbachia – and therefore be less likely to transmit disease-causing viruses.
This strategy is used by the Eliminate Dengue program, a nonprofit collaboration employing seven research institutes around the world. In test areas, Eliminate Dengue has successfully incorporated Wolbachia into mosquito populations.
In this context, an interesting aspect of Aedes aegypti behavior is their tendency not to travel far. In fact, a highway is a sufficient barrier to prevent mosquito spread. When researchers set up a release site in one city or town, they don’t see their mosquitoes travel to other areas.
This allows for controlled studies, as well as the release of these mosquitoes only where it’s been approved. The limited spread and isolated sites used were important factors in the decision to allow mosquito releases in the United States.
Eliminate Dengue is not yet active in the U.S. Instead, the U.S. is taking a different approach, looking to male rather than female mosquitoes.
Population control: The male approach
MosquitoMate is a company developed out of the University of Kentucky in Lexington by medical entomologist Stephen Dobson. Partnering with the Florida Keys Mosquito Control District, they started the release of 40,000 Wolbachia-infected male mosquitoes per week this spring.
The strategy relies on a phenomenon called cytoplasmic incompatibility (CI) to reduce mosquito populations. CI occurs when a male mosquito infected with Wolbachia mates with an uninfected female. Because Wolbachia is transmitted through the female egg, the offspring will be Wolbachia-free. But Wolbachia has already altered the father’s sperm DNA in a way that allows offspring to survive only if the fertilized egg has Wolbachia. Since the infected males will come in contact only with the naturally occurring Wolbachia-free population, their offspring will die during embryonic development – the eggs won’t hatch.
And unfortunately for the mosquitoes, females store sperm inside them to continuously fertilize their eggs. This means that the female mosquito’s first mate will be the father of all her offspring. So even if a female just mates again, once she’s partnered with a Wolbachia-infected male, all her offspring will not be viable.
The Florida Keys Mosquito District is not limiting its attack to just one approach. Beyond Wolbachia and more traditional strategies, they’re also partnering with Oxitec, a genetic engineering company. Like MosquitoMate, Oxitec also releases male mosquitoes. But, in place of Wolbachia, Oxitec genetically modifies its mosquito to contain a self-limiting gene that causes offspring to die.
The goal remains the same: Release males into the environment that will mate with females and cause all offspring to die, eventually leading to a mosquito population crash.
Male and female strategies share one goal
Each Wolbachia mosquito strategy has its strengths: The female approach is broad-reaching and should directly decrease disease transmission. The male strategy effectively lowers the local mosquito population, without releasing female nuisance mosquitoes.
The male release strategies are an important “right-now” fix, but they’ll require an annual, costly release because male mosquitoes – with either MosquitoMate’s Wolbachia or Oxitec’s self-limiting gene – cannot pass on to the next generation their crucial trait. When these males are not being released, fertile wild males will mate with females and the population will rebound.
Eliminate Dengue’s female release strategy is sustainable long-term, but it takes extensive monitoring to ensure the initial establishment of mosquitoes. While MosquitoMate and Oxitec do not disclose their costs, Eliminate Dengue hopes to make their system affordable at a cost of approximately US$1 per person.
Some members of the public have advocated against these kinds of mosquito release programs, particularly when the mosquitoes have been genetically modified, as with Oxitec’s transgenic insects. While the United States Department of Agriculture received 2,600 responses to the Oxitec plan, only one response was filed regarding MosquitoMate’s non-GMO strategy.
In the U.S., mosquito control districts are taking a cautious approach. They’re first trying the two nonpermanent male strategies in small areas. The Florida Keys will be evaluating mosquitoes on their Stock Island release site for 12 weeks. We should know how effective male Wolbachia-infected mosquitoes are at reducing populations by late summer.
This article was originally published on The Conversation website under a Creative Commons Attribution 4.0 International License. Read the original article here.
If you found this article interesting, you may be interested in browsing more content on ScienceDirect. We are pleased to offer you a free chapter from the Arthropod Vector: Controller of Disease Transmission book called “Paratransgenesis Applications: Fighting Malaria With Engineered Mosquito Symbiotic Bacteria.”
Visit elsevier.com to access content on viruses, entomology and more! Use discount code STC317 at checkout and save up to 30% on your very own copy!
Biomedicine & Biochemistry
The disciplines of biomedicine and biochemistry impact the lives of millions of people every day. Research in these areas has led to practical applications in cardiology, cancer treatment, respiratory medicine, drug development, and more. Interdisciplinary fields of study, including neuroscience, chemical engineering, nanotechnology, and psychology come together in this research to yield significant new discoveries. Elsevier’s biomedicine and biochemistry content spans a wide range of subject matter in various forms, including journals, books, eBooks, and online information services, enabling students, researchers, and clinicians to advance these fields. Learn more about our Biomedical and Biochemistry books here.